Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03685331 · ClinicalTrials.gov registry record · Phase 1

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

A Phase 1 study of Metastatic Breast Cancer and Advanced Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT03685331: Completed Phase 1 study of Metastatic Breast Cancer and Advanced Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.

NCT03685331 is a Phase 1 study of Metastatic Breast Cancer and Advanced Breast Cancer that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 9 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03685331, a Phase 1 study of Metastatic Breast Cancer and Advanced Breast Cancer, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.

Conditions Studied

Metastatic Breast Cancer Advanced Breast Cancer BRCA1 Mutation BRCA2 Mutation Locally Advanced Breast Cancer

Interventions

  • DRUG Olaparib
  • DRUG Fulvestrant
  • DRUG Palbociclib

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2020-10-15
Est. Completion 2025-12-01
Phase Phase 1
Abramson Cancer Center at Penn Medicine

402 total trials

What the finished NCT03685331 record still lists

NCT03685331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (96% lower).

The record links to 5 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.

NCT03685331 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03685331 about?

NCT03685331 is a clinical study titled "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer". The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.

What is the current status of trial NCT03685331?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-10-15. Estimated completion is 2025-12-01.

What conditions does trial NCT03685331 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, Advanced Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Locally Advanced Breast Cancer.

What interventions are being tested in trial NCT03685331?

The interventions under investigation include: Olaparib (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG).

Who is sponsoring clinical trial NCT03685331?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03685331 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03685331's enrollment target sits among peer trials

9 136th of 139 higher than 2 of 139 other Metastatic Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03685331, the US trial registry maintained by the National Library of Medicine. NCT03685331 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.